Klein, Samuel http://orcid.org/0000-0001-7127-1156
Seeley, Randy J. http://orcid.org/0000-0002-3721-5625
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (P30DK089503, R01DK133140, P01DK117821, P30DK056341, UL1TR002345)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
Article History
First Online: 19 June 2023
Competing interests
: S.K. serves on scientific advisory boards for Altimmune and Merck and as a consultant for B2M Medical. R.J.S. has received research support from Novo Nordisk, Fractyl, Astra Zeneca and Eli Lilly. R.J.S. has served as a paid consultant for Novo Nordisk, Eli Lilly, Scohia, CinRx, Fractyl, Structure Therapeutics and Congruence Therapeutics. R.J.S. has equity in Calibrate and Rewind.